Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
14,100.00    -198.00 (-1.38%)
Bid:
14,152.00
Ask:
14,154.00
Spread: 2.00 (0.014%)
Market Cap: £218.67b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Astrazeneca News

WINNERS & LOSERS: Metlen Energy takes hit from annual results delay
27 Mar 2026

WINNERS & LOSERS: Metlen Energy takes hit from annual results delay

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday.

LONDON MARKET OPEN: Stocks mixed as Brent oil nears USD110
27 Mar 2026

LONDON MARKET OPEN: Stocks mixed as Brent oil nears USD110

(Alliance News) - Stock prices in London opened mixed on Friday, with the FTSE 100 edging higher despite continued uncertainty regarding Iran peace ta...

AstraZeneca hails positive results in tozorakimab lung disease trials
27 Mar 2026

AstraZeneca hails positive results in tozorakimab lung disease trials

(Alliance News) - AstraZeneca PLC on Friday reported positive phase-three trial results for its chronic obstructive pulmonary disease treatment tozora...

LONDON BRIEFING: UK retail sales fall; GSK drug accepted for review
27 Mar 2026

LONDON BRIEFING: UK retail sales fall; GSK drug accepted for review

(Alliance News) - UK retail sales fell in the month of February but by less than expected, while GSK and AstraZeneca hailed positive clinical and regu...

AstraZeneca's COPD candidate succeeds in twin Phase III studies
27 Mar 2026

AstraZeneca's COPD candidate succeeds in twin Phase III studies

(Sharecast News) - Drugmaker AstraZeneca said on Friday that its monoclonal antibody tozorakimab had met the primary endpoint in both of its Phase III...

Daiichi Sankyo's cancer drug approved as second-line therapy in Japan
23 Mar 2026

Daiichi Sankyo's cancer drug approved as second-line therapy in Japan

(Alliance News) - Daiichi Sankyo Co Ltd announced on Monday that Japan's Pharmaceuticals and Medical Devices Agency has approved an update to the pres...